Chemical proteomics identifies heterogeneous nuclear ribonucleoprotein (hnRNP) A1 as the molecular target of quercetin in its anti-cancer effects in PC-3 cells

Journal of Biological Chemistry

Volumn 289, Issue 32, 2014, Pages 22078-22089

  Ko, Chia Chen ^a   Chen, Yun Ju ^a   Chen, Chih Ta ^a   Liu, Yu Chih ^a   Cheng, Fong Chi ^b   Hsu, Kai Chao ^a   Chow, Lu Ping ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b Eurofins Medinet Inc   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DEATH; DISEASES; FLAVONOIDS;

CANCER PREVENTION; EXPRESSION REGULATION; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN (HNRNP); MECHANISM OF ACTION; MOLECULAR TARGETS; PROSTATE CANCERS; PROTEOMICS;

PHENOLS;

ANTINEOPLASTIC AGENT; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HNRNP A1; INHIBITOR OF APOPTOSIS PROTEIN; KARYOPHERIN BETA; MUTANT PROTEIN; PROTEIN BINDING; QUERCETIN; RECOMBINANT PROTEIN; TNPO1 PROTEIN, HUMAN;

ACTIVE TRANSPORT; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BINDING SITE; BIOLOGICAL MODEL; CELL SURVIVAL; DRUG EFFECTS; GENETICS; HUMAN; MALE; METABOLISM; MOLECULAR GENETICS; PHYTOTHERAPY; PROSTATIC NEOPLASMS; PROTEOMICS; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BETA KARYOPHERINS; BINDING SITES; BIOLOGICAL TRANSPORT, ACTIVE; CELL LINE, TUMOR; CELL SURVIVAL; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN GROUP A-B; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; MUTANT PROTEINS; PHYTOTHERAPY; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEOMICS; QUERCETIN; RECOMBINANT PROTEINS;

EID: 84905851435     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.553248     Document Type: Article

References (35)

1. Gupta, S. C., Kim, J. H., Prasad, S., and Aggarwal, B. B. (2010) Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev. 29, 405-434
2. Murphy, A. B., Macejko, A., Taylor, A., and Nadler, R. B. (2009) Chronic prostatitis: management strategies. Drugs 69, 71-84
3. Vijayababu, M. R., Kanagaraj, P., Arunkumar, A., Ilangovan, R., Aruldhas, M. M., and Arunakaran, J. (2005) Quercetin-induced growth inhibition and cell death in prostatic carcinoma cells (PC-3) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression. J. Cancer Res. Clin. Oncol. 131, 765-771
4. Kumar, R., Verma, V., Jain, A., Jain, R. K., Maikhuri, J. P., and Gupta, G. (2011) Synergistic chemoprotective mechanisms of dietary phytoestrogens in a select combination against prostate cancer. J. Nutr. Biochem. 22, 723-731
5. Lamson, D. W., and Brignall, M. S. (2000) Antioxidants and cancer, part 3: quercetin. Altern. Med. Rev. 5, 196-208
6. Lee, K. W., Kang, N. J., Heo, Y. S., Rogozin, E. A., Pugliese, A., Hwang, M. K., Bowden, G. T., Bode, A. M., Lee, H. J., and Dong, Z. (2008) Raf and MEKprotein kinases are direct molecular targets for the chemopreventive effect of quercetin, a major flavonol in red wine. Cancer Res. 68, 946-955
7. Lee, K. M., Hwang, M. K., Lee, D. E., Lee, K. W., and Lee, H. J. (2010) Protective effect of quercetin against arsenite-induced COX-2 expression by targeting PI3K in rat liver epithelial cells. J. Agric. Food Chem. 58, 5815-5820
8. Wang, R. E., Hunt, C. R., Chen, J., and Taylor, J. S. (2011) Biotinylated quercetin as an intrinsic photoaffinity proteomics probe for the identification of quercetin target proteins. Bioorg. Med. Chem. 19, 4710-4720
9. Duncan, J. S., Turowec, J. P., Duncan, K. E., Vilk, G., Wu, C., Lüscher, B., Li, S. S., Gloor, G. B., and Litchfield, D. W. (2011) A peptide-based target screen implicates the protein kinase CK2 in the global regulation of caspase signaling. Sci. Signal. 4, ra30
10. Piersma, S. R., Labots, M., Verheul, H. M., and Jiménez, C. R. (2010) Strategies for kinome profiling in cancer and potential clinical applications: chemical proteomics and array-based methods. Anal. Bioanal. Chem. 397, 3163-3171
11. Ermakova, S., Choi, B. Y., Choi, H. S., Kang, B. S., Bode, A. M., and Dong, Z. (2005) The intermediate filament protein vimentin is a new target for epigallocatechin gallate. J. Biol. Chem. 280, 16882-16890
12. Fleischer, T. C., Murphy, B. R., Flick, J. S., Terry-Lorenzo, R. T., Gao, Z. H., Davis, T., McKinnon, R., Ostanin, K., Willardsen, J. A., and Boniface, J. J. (2010) Chemical proteomics identifies Nampt as the target of CB30865, an orphan cytotoxic compound. Chem. Biol. 17, 659-664
13. Curtis Nickel, J., Shoskes, D., Roehrborn, C. G., and Moyad, M. (2008) Nutraceuticals in prostate disease: the urologist's role. Rev. Urol. 10, 192-206
14. Marcinkiewicz, C., Gałasiński, W., and Gindzieński, A. (1995) EF-1 α is a target site for an inhibitory effect of quercetin in the peptide elongation process. Acta Biochim. Pol. 42, 347-350
15. Han, S. P., Tang, Y. H., and Smith, R. (2010) Functional diversity of the hnRNPs: past, present and perspectives. Biochem. J. 430, 379-392
16. Bevilacqua, E., Wang, X., Majumder, M., Gaccioli, F., Yuan, C. L., Wang, C., Zhu, X., Jordan, L. E., Scheuner, D., Kaufman, R. J., Koromilas, A. E., Snider, M. D., Holcik, M., and Hatzoglou, M. (2010) eIF2′ phosphorylation tips the balance to apoptosis during osmotic stress. J. Biol. Chem. 285, 17098-17111
17. Schimmer, A. D. (2004) Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res. 64, 7183-7190
18. Gill, C., Dowling, C., O'Neill, A. J., and Watson, R. W. (2009) Effects of cIAP-1, cIAP-2 and XIAP triple knockdown on prostate cancer cell susceptibility to apoptosis, cell survival and proliferation. Mol. Cancer 8, 39
19. Qi, Y., and Xia, P. (2012) Cellular inhibitor of apoptosis protein-1 (cIAP1) plays a critical role in beta-cell survival under endoplasmic reticulum stress: promoting ubiquitination and degradation of C/EBP homologous protein (CHOP). J. Biol. Chem. 287, 32236-32245
20. Al-Maghrebi, M., Anim, J. T., and Olalu, A. A. (2005) Up-regulation of eukaryotic elongation factor-1 subunits in breast carcinoma. Anticancer Res. 25, 2573-2577
21. Liu, H., Ding, J., Chen, F., Fan, B., Gao, N., Yang, Z., and Qi, L. (2010) Increased expression of elongation factor-1′ is significantly correlated with poor prognosis of human prostate cancer. Scand. J. Urol. Nephrol. 44, 277-283
22. Ruiz, C., Holz, D. R., Oeggerli, M., Schneider, S., Gonzales, I. M., Kiefer, J. M., Zellweger, T., Bachmann, A., Koivisto, P. A., Helin, H. J., Mousses, S., Barrett, M. T., Azorsa, D. O., and Bubendorf, L. (2011) Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer. J. Pathol. 223, 543-552
23. Ginisty, H., Sicard, H., Roger, B., and Bouvet, P. (1999) Structure and functions of nucleolin. J. Cell Sci. 112, 761-772
24. Sengupta, T. K., Bandyopadhyay, S., Fernandes, D. J., and Spicer, E. K. (2004) Identification of nucleolin as an AU-rich element binding protein involved in bcl-2 mRNA stabilization. J. Biol. Chem. 279, 10855-10863
25. Hovanessian, A. G., Soundaramourty, C., El Khoury, D., Nondier, I., Svab, J., and Krust, B. (2010) Surface expressed nucleolin is constantly induced in tumor cells to mediate calcium-dependent ligand internalization. PLoS One 5, e15787
26. Christian, S., Pilch, J., Akerman, M. E., Porkka, K., Laakkonen, P., and Ruoslahti, E. (2003) Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J. Cell Biol. 163, 871-878
27. Lewis, S. M., Veyrier, A., Hosszu Ungureanu, N., Bonnal, S., Vagner, S., and Holcik, M. (2007) Subcellular relocalization of a trans-acting factor regulates XIAP IRES-dependent translation. Mol. Biol. Cell 18, 1302-1311
28. Patry, C., Bouchard, L., Labrecque, P., Gendron, D., Lemieux, B., Toutant, J., Lapointe, E., Wellinger, R., and Chabot, B. (2003) Small interfering RNA-mediated reduction in heterogeneous nuclear ribonucleoparticule A1/A2 proteins induces apoptosis in human cancer cells but not in normal mortal cell lines. Cancer Res. 63, 7679-7688
29. Pino, I., Pío, R., Toledo, G., Zabalegui, N., Vicent, S., Rey, N., Lozano, M. D., Torre, W., García-Foncillas, J., and Montuenga, L. M. (2003) Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer. Lung Cancer 41, 131-143
30. Ma, Y. L., Peng, J. Y., Zhang, P., Huang, L., Liu, W. J., Shen, T. Y., Chen, H. Q., Zhou, Y. K., Zhang, M., Chu, Z. X., and Qin, H. L. (2009) Heterogeneous nuclear ribonucleoprotein A1 is identified as a potential biomarker for colorectal cancer based on differential proteomics technology. J. Proteome Res. 8, 4525-4535
31. Guil, S., Long, J. C., and Cáceres, J. F. (2006) hnRNP A1 relocalization to the stress granules reflects a role in the stress response. Mol. Cell Biol. 26, 5744-5758
32. Russo, M., Spagnuolo, C., Tedesco, I., Bilotto, S., and Russo, G. L. (2012) The flavonoid quercetin in disease prevention and therapy: facts and fancies. Biochem. Pharmacol. 83, 6-15
33. Walker, E. H., Pacold, M. E., Perisic, O., Stephens, L., Hawkins, P. T., Wymann, M. P., and Williams, R. L. (2000) Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell 6, 909-919
34. Schirle, M., Bantscheff, M., and Kuster, B. (2012) Mass spectrometrybased proteomics in preclinical drug discovery. Chem. Biol. 19, 72-84
35. Bantscheff, M., and Drewes, G. (2012) Chemoproteomic approaches to drug target identification and drug profiling. Bioorg. Med. Chem. 20, 1973-1978